Form 4: Catalyst Pharmaceuticals Chief Strategy Officer Sells Over 3,900 Shares

Preethi Sundaram, Chief Strategy Officer of Catalyst Pharmaceuticals, Inc. (CPRX), reported the sale of 3,924 shares of common stock for personal reasons in early June 2025.

Summary

• Preethi Sundaram, Chief Strategy Officer of Catalyst Pharmaceuticals, Inc. (CPRX), sold a total of 3,924 shares of the company's common stock.
• On June 10, 2025, Ms. Sundaram sold 2,324 shares at a weighted average price of $26.41 per share, with prices ranging from $26.39 to $26.49.
• On June 11, 2025, an additional 1,600 shares were sold at a weighted average price of $26.42 per share, with prices ranging from $26.39 to $26.48.
• Following these transactions, Ms. Sundaram beneficially owns 41,081 shares of Catalyst Pharmaceuticals common stock.
• The sales were conducted for personal reasons and are explicitly stated not to be a result of any disagreement with the Company.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to insider selling, which can be perceived as a lack of confidence, although the stated 'personal reasons' and 'no disagreement' mitigate a stronger negative interpretation.

Positives

• The filing explicitly states that the share sales were for personal reasons and not due to any disagreement with Catalyst Pharmaceuticals, which may alleviate concerns about internal conflict or lack of confidence in the company's direction.

Negatives

• Insider selling, even for personal reasons, can sometimes be perceived negatively by the market as it might suggest that an insider believes the stock is fully valued or that future growth prospects are limited.

Risks

• The sale of shares by a key executive like the Chief Strategy Officer could lead to negative market sentiment or speculation, potentially impacting the company's stock price.

Future Outlook

NA

Management Comments

• "Shares were sold on the open market for personal reasons and not as a result of any disagreement with the Company."

Industry Context

NA

Stakeholder Impact

• Shareholders may view the insider sale as a potential signal regarding the company's future performance or stock valuation, which could influence their investment decisions.

Key Dates

Recommendation

Keywords

Catalyst Pharmaceuticals, CPRX, Insider Trading, Form 4, Stock Sale, Preethi Sundaram, Chief Strategy Officer, Beneficial Ownership